Molecular Pharmacology Program
The Michael Kharas Lab
Nguyen DTT, Lu Y, Chu KL, Yang X, Park SM, Choo ZN, Chin CR, Prieto C, Schurer A, Barin E, Savino AM, Gourkanti S, Patel P, Vu LP, Leslie CS, Kharas MG. HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells. Nat Commun. 2020 Apr 24;11(1):2026.
Cheng Y, Luo H, Izzo F, Pickering BF, Nguyen D, Byers R, Schurer A, Gourkanti S, Bruning J, Vu L,Jaffrey S, Landau D, Kharas MG*. RNA methylation maintains hematopoietic stem cell identity and symmetric commitment. Cell Reports. 2019 August 13. 7:1703-11716.
Minuesa G, Albanese SK, Wei X, Kazansky Y, Worroll D, Chow A, Schurer A, Park S-M, Rotsides CZ, Taggart J, Rizzi A, Naden LN, Chou T, Gourkanti S, Cappel D, Passarelli MC, Fairchild L, Adura C, Glickman JF, Schulman J, Famulare C, Patel M, Eibl JK, Ross GM, Bhattacharya S, Tan D, Leslie C, Beuming T, Patel DJ, Goldgur Y, Chodera JD, Kharas MG*. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat. Comm. 2019 June 19; 10.
Park SM, Cho H, Thornton AM, Barlowe TS, Chou T, Chhangawala S, Fairchild L, Taggart J, Chow A, Schurer A, Gruet A, Witkin MD, Kim JH, Shevach EM, Krivtsov A, Armstrong SA, Leslie C, Kharas MG.IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. Cell Stem Cell.2019 Jan 3;24(1):153-165.e7.
Michael G. Kharas, PhD
- Cancer biologist Michael Kharas studies RNA regulators of self-renewal in both normal and leukemic hematopoiesis.
- PhD, University of California Irvine
- Email Address
- Leukemia and Lymphoma Society Career Development Award (2017)
- Alex Lemonade Stand Foundation ‘A’ Award (2016)
- American Society of Hematology Junior Faculty Scholar Award (2011)
- Kimmel Scholar Award (2013)
- V-Scholar Award (2013)
Postdoctoral positions are available for highly motivated candidates with a background in molecular biology to join our group.
Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it.
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael G. Kharas discloses the following relationships and financial interests:
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.